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Abstract
Background: The transcriptional repressor DREAM (downstream regulatory element antagonist modulator) controls
the expression of prodynorphin and has been involved in the modulation of endogenous responses to pain. To
investigate the role of DREAM in central mechanisms of pain sensitization, we used a line of transgenic mice (L1)
overexpressing a Ca
2+- and cAMP-insensitive DREAM mutant in spinal cord and dorsal root ganglia.
Results: L1 DREAM transgenic mice showed reduced expression in the spinal cord of several genes related to pain,
including prodynorphin and BDNF (brain-derived neurotrophic factor) and a state of basal hyperalgesia without
change in A-type currents. Peripheral inflammation produced enhancement of spinal reflexes and increased
expression of BDNF in wild type but not in DREAM transgenic mice. The enhancement of the spinal reflexes was
reproduced in vitro by persistent electrical stimulation of C-fibers in wild type but not in transgenic mice. Exposure
to exogenous BDNF produced a long-term enhancement of dorsal root-ventral root responses in transgenic mice.
Conclusions: Our results indicate that endogenous BDNF is involved in spinal sensitization following inflammation
and that blockade of BDNF induction in DREAM transgenic mice underlies the failure to develop spinal
sensitization.
Background
Transcriptional repressor activity of DREAM depends
on their high affinity Ca
2+-d e p e n d e n tb i n d i n ga sah e t -
erotetramer to DRE (downstream regulatory element)
sites in target genes [1-4]. Increased levels of intracellu-
lar Ca
2+ result in DREAM unbinding from DNA and
transcriptional derepression [1]. Binding to DRE sites is
controlled also by the interaction with other nucleopro-
teins [5,6]. DREAM mutants unable to respond to Ca
2+,
cAMP and/or to establish protein-protein interactions,
function as cross-dominant constitutively active mutants
(daDREAM) and repress permanently target genes in
vivo [7,8]. Several genes have been shown to be regu-
lated by DREAM, including prodynorphin, c-fos [1],
AA-NAT, ICER [3], and BDNF [9] NCX-3 [8] and sev-
eral cytokines in T lymphocytes [7]. DREAM, also
known as calsenilin or KChIP-3 (K
+ channel interacting
protein 3), interacts with presenilins or Kv4 potassium
channels, respectively [10,11].
Genetic ablation of DREAM in DREAM
-/- mice results
in increased thresholds for noxious stimuli that have
been associated to increased prodynorphin gene expres-
sion and to reduction in A-type currents (IA)i ns p i n a l
cord neurons [12-14]. However, reduction of A-type
currents in spinal cord neurons of Kv4.2 deficient mice
are associated with thermal and mechanical hyperalgesia
and reduced responses to inflammation [15].
BDNF is implicated in the maintenance of peripheral
sensory neurons during development and in the regula-
tion of synaptic plasticity and long-term potentiation in
the adult brain and spinal cord [16-19]. Expression of
the BDNF gene depends on several regulatory regions
[20]. Activity-dependent BDNF induction, following pain
stimulation, is mainly controlled by regulatory elements
in exon III in the rat gene. This includes, a hemi-palin-
dromic CRE site that mediates CaMK IV-dependent
transactivation by CREB/CBP following neuronal depo-
larization [21,22], two Ca
2+-responsive elements, the
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(CaRF) [23] and a DRE site that binds the transcrip-
tional repressor DREAM [9].
Here we used transgenic mice expressing a cross-
dominant constitutively active DREAM mutant to
further analyze the functional role of DREAM in pain
transmission and sensitization. Behavioral studies
revealed that DREAM transgenic mice possess high sen-
sitivity to thermal and chemical noxious stimuli and
reduced hyperalgesic response to inflammation. Electro-
physiological studies performed in isolated spinal cord
o fD R E A Mt r a n s g e n i cm i c ei n d i c a t et h ea b s e n c eo f
hyperreflexia, a sign of sensitization [24], in response to
persistent activation of nociceptive afferents. Quantita-
tive real time-PCR showed that basal and inducible
expression of BDNF is reduced in spinal cord and dorsal
root ganglia (DRG) from DREAM transgenic mice.
Though expression of the constitutively active DREAM
mutant might affect the expression of several down-
stream genes, BDNF supplementation is enough to
restore the capability of the spinal cord of DREAM
transgenic mice to develop hyperreflexia.
Results
Characterization of L1 daDREAM transegenic mice
Regulation of prodynorphin gene expression by DREAM
has been associated with changes in the response to
noxious stimuli [12,13] and learning [14]. To specifically
analyze the role of DREAM in the molecular pathways
that control the response to pain we used a line of
transgenic mice (L1) expressing a cross-dominant con-
stitutively active DREAM mutant (daDREAM) in neu-
rons under the control of the CamKIIa promoter [25].
The ratio of daDREAM mRNA to endogenous DREAM
was 1.6 to 1 and 1 to 3 in spinal cord and DRG, respec-
tively (Figure 1A), indicating that in both areas the
expression of the dominant mutant is enough to block
endogenous DREAM-dependent derepression [7,8].
Expression of daDREAM in the spinal cord of L1 mice
was observed early after birth and at postnatal day 7,
daDREAM levels were not different from those in adult
mice (Figure 1B). Another DREAM transgenic line
(L26), with similar high expression of daDREAM in tele-
ncephalic areas as L1 (data not shown) but with very
low expression in spinal cord and DRG (Figure 1A), was
included in some experiments as a negative control. In
transgenic L1 mice, expression of b-galactosidase, used
as reporter gene in the bicistronic transgenesis cassette,
could be observed in many neurons across all laminae
of the spinal cord, with greater density in the dorsal
horn and laminae X (Figure 1C). Expression of
daDREAM protein in L1 mice resulted in a significant
reduction in the basal levels of prodynorphin and BDNF
mRNA in the lumbar spinal cord (Figure 1D). Expres-
sion of BDNF was reduced also in DRG, while levels of
the TrkB receptor were not modified in the spinal cord
or DRG (Figure 1E). Accordingly, no significant changes
in dynorphin or BDNF expression were observed in
spinal cord from line 26 mice (Figure 1D).
Basal hyperalgesia and delayed sensitization to noxious
stimuli in daDREAM transgenic mice
Both transgenic lines developed normally to adulthood
but line 1 mice showed enhanced response to thermal
and visceral noxious stimuli in basal conditions com-
pared to wild type littermates or L26 mice, however,
response to mechanical stimulation was not different in
L1 and wild type mice (Figure 2A). Intraplantar injection
of complete Freund’s adjuvant (CFA) or carrageenan
produced similar redness and paw inflammation in wild
type and L1 mice (Figure 2B). At 24 hours after CFA,
wild type mice developed a pronounced thermal hyper-
algesia (withdrawal latency of 1.29 ± 0.02 seconds),
which lasted 18 days (Figure 2C). On the contrary, ther-
mal thresholds were slightly modified in transgenic mice
24 hours after CFA and the hyperalgesic response
was observed only up to day 12 after CFA (Figure 2C).
Similar results were obta i n e dw h e nw et e s t e df o r
mechanical sensitivity. Wild type mice displayed a
strong hyperalgesic response starting from day 1 after
CFA injection, while in transgenic mice the hyperalgesia
was less pronounced (Figure 2C). These data suggest
that daDREAM mice display impaired response to
inflammatory pain with milder and shorter-lasting
hyperalgesia compared to wild type mice.
Increased spinal reflexes in daDREAM mice
Segmental spinal cord circuits underlay motor withdra-
wal reflexes to nociceptive stimuli such as those used in
behavioural pain testing. Therefore we analyzed dorsal
root-ventral root reflexes (DR-VRRs) in wild type and
transgenic mice using a spinal cord in vitro preparation
from P9 mice [26]. Consistent with a basal hypersensi-
tivity, responses to single stimuli of a wide range of
intensities activating A- and C-fibres were increased in
L1 mice (Figure 3A). The responses to trains of stimuli
of C-fibre intensity consistently led to larger spike
counts in L1 mice, while the slope of the resulting
wind-up effect was not modified (Figure 3B). In contrast
to the increased responsiveness of the spinal cord in L1
mice, nerve conduction velocities and electrical thresh-
olds for A- and C-fibres were not significantly different
f r o mt h o s eo fw i l dt y p em i c e( F i g u r e3 C ) .T h e s er e s u l t s
suggest that the basal hyperalgesia observed in L1 mice
may be related to an enhanced spinal processing of
afferent signals rather than changes in afferent fibres.
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Page 2 of 14A-type currents in spinal cord neurons from L1 mice are
normal
A-type currents have been associated with neuronal
plasticity in the hippocampus [27] and the spinal cord
[15]. The Ca
2+-insensitive DREAM/KChIP3 mutant has
been previously shown to affect gating of Kv4 potassium
channels in vitro [11] and a weak change in A-type
currents has been reported in DREAM deficient neurons
[ 1 2 ] .W ei n v e s t i g a t e dw h e t h e rac h a n g ei nA - t y p ec u r -
rents in dorsal horn neurons from L1 mice could
contribute to the basal hyperalgesia observed in
daDREAM mice.
Neurons from wild type and L1 mice were recorded in
current clamp mode to compare their general state of
excitability. No differences were found in resting poten-
tial, input resistance and action potential threshold and
amplitude (Table 1). Intracellular depolarizing current
pulses of 500 ms and increasing intensities produced
similar numbers of action potentials in both groups
(Figure 4A), suggesting that the intrinsic excitability of
Figure 1 Expression of DREAM, daDREAM and DREAM targets in spinal cord and dorsal root ganglia. (A) Quantitative real-time PCR
analysis of the expression of dominant active DREAM (daDREAM) in spinal cord (SC) and dorsal root ganglia (DRG) in transgenic L1 and L26
mice. For comparison, expression levels of endogenous DREAM (endoDREAM) are shown. (B) Comparison of the expression of dominant active
DREAM mutant in spinal cord at P7 and adult in wild type (wt) and L1 mice. (C) b-galactosidase positive cells show the distribution of the
transgene in lamina I-II and X in the spinal cord of L1 mice. (D) Quantitative real-time PCR analysis of the expression of prodynorphin (Dyn) and
brain-derived neurotrophic factor (BDNF) in spinal cord from wild type (wt) and transgenic L1 and L26 mice. (E) Quantitative real-time PCR
analysis of the expression of BDNF mRNA and its receptor, tyrosine receptor kinase B (TrkB) in DRG and spinal cord from wild type (wt) and L1
mice. The mRNA levels in A, B, D and E are expressed as ratio to HPRT mRNA levels. Data are mean ± SEM (n = 6-9 in A and B and 5-7 in D and
E). *** P < 0.001.
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clamp recordings in dorsal horn neurons allowed the
isolation of A-type currents, which were similar in wild
type and L1 mice (Figure 4B-D). No differences between
groups were found in the voltage dependent activation
and inactivation curves, current density and reactivation
( F i g u r e4 E ,Fa n dT a b l e1 ) .T h e s ed a t ai n d i c a t et h a t
daDREAM does not function as a dominant mutant for
the spinal modulation of Kv4 potassium channel activity
in vivo, and it is therefore unlikely that the basal hyper-
algesia observed in L1 mice is related to changes in
A-type currents.
Quantitative analysis of the mRNA levels of different
Kv subunits contributing to A-type currents in spinal
cord from P7 mice showed small but significant
increases of Kv4.2 and Kv4.3 in daDREAM mice, while
Figure 2 Basal hyperalgesia and impaired sensitization after inflammation in transgenic mice. (A) Basal sensitivity to nociceptive
stimulation in the indicated tests in wild type (wt) and transgenic L1 and L26 mice. (B) Inflammatory response in wild type (wt) and transgenic
L1 mice 24 h after intraplantar injection of carrageenan. (C) Nociceptive thresholds in the plantar and the Von Frey tests before and at the
indicated days after intraplantar injection of complete Freund’s adjuvant (CFA) in wild type (wt) and transgenic L1 mice. * Refers to comparison
with wild type and # refers to comparison with day 0. Statistically significant differences between groups (n = 10) were measured by One-way
ANOVA with Bonferroni post test. * or #, P < 0.05; ** or ##, P < 0.01; ***, P < 0.001.
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Page 4 of 14Figure 3 The basal responsiveness of spinal cords from L1 mice is increased. Comparison of ventral root responses to dorsal root
stimulation obtained from wild type (wt) (n = 10) and L1 (n = 11) mice. (A) The intensity-response curve shows the number of spikes elicited by
single stimuli of increasing intensities. Responses in L1 mice were larger (overall ANOVA, P < 0.01). (B) The wind-up curve shows number of
spikes in ventral root recordings to trains of stimuli at C-fibre intensity (1 Hz). Responses in L1 mice were greater (overall ANOVA, P < 0.001). (C)
Comparison of the conduction velocity in A- and C-fibers in wild type (wt) and L1 mice.
Rivera-Arconada et al. Molecular Pain 2010, 6:95
http://www.molecularpain.com/content/6/1/95
Page 5 of 14Kv4.1 and Kv3.4 levels were unaffected (Figure 5).
Reduced expression of Kv4 subunits has been associated
with basal hyperalgesia [15]. In L1 mice, the hyperalgesia
was observed in the presence of a moderate up-regula-
tion of Kv4 subunits, which however did not lead to
significant changes in A-type currents recorded in dorsal
horn neurons.
Lack of spinal sensitization in L1 mice following
inflammation and low frequency stimulation of C-fibres
Since the hyperalgesic response to peripheral inflamma-
tion is reduced in L1 mice, we analyzed changes in
spinal cord function after inflammation. Spinal cords
from carrageenan-treated wild type P9 mice showed
large and significant increases in DR-VRRs to single
(Figure 6A) and repetitive stimuli (Figure 6B) compared
to nontreated wild type mice. In contrast, the same
treatment failed to produce differences in spinal reflexes
in L1 mice (Figure 6C, D).
In order to model in vitro the central sensitization
induced by inflammation in wild type mice, we used a
protocol of low frequency stimulation of the dorsal
roots similar to that reported to produce LTP in superfi-
cial dorsal horn neurons [28]. In isolated spinal cords
from wild type mice, application of a conditioning pro-
tocol consisting of a low frequency and prolonged sti-
mulation of C-fibres resulted in long-term enhancement
of DR-VRRs (Figure 7A, B), whereas application of an
identical conditioning protocol at A-fiber intensity did
not produce changes in DR-VRRs (Figure 7B, bottom
panel). The enhancement developed slowly within the
first hour post-conditioning, reached a plateau between
2 and 3 h and was still observed 4 h after application of
the conditioning stimulus, the longest recorded period.
In L1 mice, application of the conditioning stimuli at
C-fibre intensity did not produce the enhancement of
DR-VRRs (Figure 7A, B). After inflammation, persistent
stimulation of C-fibres increased ventral responses to
dorsal root stimulation of different intensities in spinal
cords from wild type mice (Figure 7C) but not in trans-
genic spinal cords (Figure 7D), indicating that L1 mice
are unable to generate central sensitization.
BDNF mediates long-term enhancement of DR-VRRs
BDNF is believed to play an important role in spinal
plasticity and sensitization following carrageenan-inflam-
mation [29]. Therefore, we investigated whether reduced
spinal levels of BDNF could be responsible for the lack
of central sensitization observed in transgenic mice.
F i r s tw ea n a l y z e dw h e t h e rt h ep r e s e n c eo fB D N Fi s
necessary for segmental spinal circuits to generate a
long-term enhancement of DR-VRRs in response to the
prolonged low frequency C-fibre stimulation protocol.
For this, we used BDNF
-/- and BDNF
-/+ P9 mice. Iso-
lated spinal cords from BDNF
-/- mice did not respond
to the C-fibre conditioning protocol, while those from
BDNF
-/+ mice showed a deficient enhancement of DR-
VRRs (Figure 8A).
We then analyzed changes in DR-VRRs before and
after exogenous applications of BDNF to spinal cords of
wild type and L1 mice. Consistent with our previous
result that TrkB receptor mRNA levels are not modified
in L1 mice, the response to exogenous addition of BDNF
was similar in spinal cords from wild type and L1 mice
( F i g u r e8 B ,C ) .I nb o t hc a s e s ,B D N Fs u p e r f u s i o np r o -
duced a significant 2-fold increase in spikes associated to
the DR-VRRs elicited by a wide range of stimulus intensi-
ties involving activation of A- and C-fibres.
These results indicate that BDNF is essential for the
development of spinal sensitization and suggest that
sensitization would occur in L1 mice if they could mobi-
lize enough BDNF in response to persistent activation of
nociceptive afferents i.e. chronic inflammation or in
response to injury. To test this hypothesis we analyzed
the expression of BDNF mRNA in DRG and BDNF pro-
tein in spinal cord following the application of CFA.
Importantly, the inflammatory response in wild type
mice developed with an increase in BDNF mRNA levels
that was maximal at 3 days and remained elevated 5
days after CFA injection (Figure 8D). In DRG from L1
mice, however, levels of BDNF mRNA were not
increased at any time after CFA injection (Figure 8D).
Importantly, western blot analysis of BDNF protein
levels in spinal cord confirmed the mRNA data and
showed a 70% decrease in BDNF protein levels in
Table 1 Basic electrophysiological properties (current-
clamp) and major traits for transient (IA) currents
(voltage-clamp) of neurons from wild type and
transgenic mice
Wild type Transgenic
Current-clamp
Number of neurons 19 8
RMP
a (mV) -55.7 ± 0.8
f -53.9 ± 1.2
Rin
b (MΩ) 355 ± 20 387 ± 57
AP-A
c (mV) 65 ± 2 68 ± 3
AP-T
d (mV) -39.7 ± 0.7 -40.1 ± 1.3
Voltage-clamp
Number of neurons 18 7
Max current density (pA/pF) 15.3 ± 3.3 14.5 ± 8.4
Time constant (ms) 15.9 ± 1.5 15.7 ± 2.8
Activation; V50
e (mV) -22.5 ± 2.1 -20.1 ± 2.6
Activation; slope factor 8.4 ± 0.7 6.5 ± 0.7
Inactivation; V50
e (mV) -43.9 ± 1.7 -40.1 ± 2.5
Inactivation; slope factor -10.5 ± 1.0 -9.5 ± 0.9
a resting membrane potential;
b input resistance;
c action potential amplitude;
d action potential threshold;
e voltage of half maximal activation or
inactivation;
f mean ± SEM.
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Page 6 of 14Figure 4 General excitability and IA currents in spinal cord are identical in wild type and L1 mice. (A) Mean number of action potentials
obtained in current clamp recordings in response to depolarizing current pulses of different intensities. Wild type (wt) and L1 mice show similar
behaviour. (B) The two-step protocol used to isolate IA current. Superimposed current (upper) and voltage (lower) traces (left) and current
isolated by subtraction in control (upper) and after perfusion of 4-AP (lower) recordings (right) is shown. (C and D) Recordings obtained from
dorsal horn neurons in control conditions show voltage-dependency of inactivation (C) and recovery from inactivation (D) of transient currents.
(E, F) Analysis of the IA current in dorsal horn neurons in wild type (wt) and L1 mice. Transient currents show the same characteristics in both
groups in terms of activation (E, right axis conductance) and inactivation kinetics (E, left axis current) and recovery from inactivation
(conductance) (F). Graphs in E show pooled data of dorsal horn neurons from wild type (n = 18) and L1 (n = 6) mice. Graphs in F were
obtained from neurons from wild type (n = 5) and L1 (n = 3) mice.
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upon inflammation (Figure 8E). Conversely, a substantial
increase in BDNF protein was readily observed in wild
type mice upon inflammation (Figure 8E).
Discussion
The dominant active mutant, daDREAM, blocks the
regulated activity of endogenous DREAM/KChIP pro-
teins when transgenic to endogenous mRNA ratio is
as low as 1 to 6 [7]. In this study, we show that in L1
transgenic mice the ratio daDREAM/DREAM mRNA
is 1.6 to 1 and 1 to 3 in spinal cord and DRG, respec-
tively, indicating that the expression of the dominant
active mutant protein is sufficient to block Ca
2+-a n d
cAMP-mediated derepression by endogenous DREAM/
KChIP proteins. As a result, expression of prodynor-
phin and BDNF, two potential targets for transrepres-
sion by DREAM that are related to pain, are reduced
in DRG and spinal cord from L1 transgenic mice.
Since the mutation at the LCD domain in daDREAM
prevents its interaction with CREB [6], downregulation
of prodynorphin and BDNF in L1 mice is not related
to interference with CREB-dependent transcription and
is due to direct repression by daDREAM. Importantly,
changes in nociception are related to the expression
of the transgene in spinal cord and DRG neurons,
since sensory thresholds were normal in L26 mice in
which daDREAM expression is confined exclusively
to telencephalic areas. In the same way, another line
of daDREAM mice, L33, without transgene expres-
sion in spinal cord and DRG neurons, did not show
a n yc h a n g ei np a i ns e n s i t i v i ty to thermal stimulation
[30].
Previous work with DREAM
-/- mice [12] demonstrated
the involvement of this transcriptional repressor in pain
modulation. Mice lacking DREAM showed a basal state
of analgesia and reduced response to inflammatory and
neuropathic treatments, that was interpreted as caused
by elevated spinal cord levels of dynorphin A peptide
observed in these mice [12]. Consistent with this, the
reduced expression of prodynorphin in L1 mice could
account for the basal state of hyperalgesia found in
adult mice. The basal hyperalgesia was paralleled by
increased hyperreflexia in the isolated spinal cord with-
out signs of change in the function of sensory afferents,
suggesting that the exaggerated sensitivity is related to
changes in spinal processing of afferent signals.
Activation of NMDA receptors plays a central role in
the transmission of primary sensory information in the
spinal cord [reviewed in [31]]. Recently, it has been
shown that DREAM reduces the amplitude of NMDA
currents in hippocampal neurons through a Ca
2+-sensi-
tive interaction between DREAM and PSD95 [30] or
between DREAM and the NR1 subunit of the receptor
[32]. On the other hand, it was previously shown that
release of dynorphin peptides from presynaptic term-
inals inhibits glutamatergic trasmission through NMDA
receptors [33]. The increased hyperreflexia in isolated
spinal cord and the increased basal sensitivity to pain
stimulation suggest that a potential reduction in NMDA
currents in spinal cord neurons in daDREAM transgenic
mice is compensated by the reduced inhibition due to
the low expression of prodynorphin.
In addition to the hypothesis of prodynorphin involve-
ment, there is a convergence of data suggesting that
transient A-type potassium currents, mediated by Kv4
channels, are responsible for hypersensitivity to acute
pain stimuli. Genetic elimination of Kv4.2 reduces A-
type currents and increases excitability of dorsal horn
neurons, resulting in enhanced sensitivity to noxious sti-
muli [15], that resembles the scenario in L1 mice. More-
over, genetic ablation of Kv channels results in
decreased expression of DREAM/KChIP proteins [34],
suggesting a genetic auto-regulatory loop between these
two gene families. Our results, however, are not consis-
tent with the hypothesis that reduced expression of Kv
channels in the spinal cord or malfunction of the asso-
ciated currents, are responsible for the altered noxious
sensitivity in L1 transgenic mice. On the contrary, we
found small but significant increase in Kv4.2 and Kv4.3
mRNA levels in the spinal cord and, more important,
w ef o u n dt h a tI A currents in dorsal horn neurons from
L1 mice were indistinguishable from those of wild type
mice in terms of various properties, including current
density and kinetics.
Reduced prodynorphin levels may explain basal hyper-
sensitivity of L1 mice, however, does not account for
Figure 5 Expression of Kv4 channels is increased in L1 mice.
Quantitative real-time PCR analysis of the different potassium
channels that participate in the generation of A-type currents in the
spinal cord. The mRNA levels in wild type (wt) and transgenic L1
mice are expressed as ratio to HPRT mRNA levels. Data are mean ±
SEM (n = 8). ** P < 0.01.
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ing CFA injection. Importantly, isolated transgenic
spinal cords were not capable to show signs of central
sensitization, which may be causal for the anomalous
response to inflammatory stimuli. Whereas spinal cords
from carrageenan-treated wild type mice showed a
marked hyperreflexia, L1 mice with or without treat-
ment, showed essentially similar spinal reflexes. Further-
more, persistent low frequency stimulation of primary
C-afferents caused a long-term enhancement of DR-
VRRs in wild type but not in L1 mice. It is worth not-
ing, that similar protocols of stimulation [35] have been
shown to produce LTP in superficial laminae neurons in
a process that resembles central sensitization induced by
inflammation.
In order to understand how L1 mice fail to produce a
normal process of central sensitization, we considered
the reduced expression levels of BDNF in L1 mice.
Reduced BDNF levels in vivo confirm previous in vitro
studies showing the regulatory effect of DREAM on
BDNF promoter activity [9]. Several lines of evidence
relate BDNF with central sensitization; i) intrathecal
administration of exogenous BDNF produces hyperalge-
sia in wild type mice, whereas administration of anti-
serum directed against either BDNF or TrkB receptors
prevent inflammation-induced hyperalgesia [29,36], ii)
conditional BDNF knockout mice do not develop hyper-
algesia after inflammatory stimuli [37] and iii) at the
functional level, BDNF has been shown to be required
for simple forms of spinal reflex plasticity like wind-up
[38] and to enhance the spinal response to sensory
inputs [16,39] through post-synaptic NMDA receptors
[16] or by reversing chloride gradients in central afferent
terminals [17]. Here we show that BDNF is required
a l s of o rl o n g e rl a s t i n gf o r m so fp l a s t i c i t yi ns p i n a l
reflexes. BDNF
-/- mice did not develop long-term
Figure 6 L1 mice lack sensitization.( Aa n dC )T h en u m b e ro fs p i k e si nv e n t r a lr o o tr e s p onses to single dorsal root stimuli of increasing
intensities and (B and D) to trains of C-fiber intensity stimuli is shown. Responses in spinal cords from non-treated (Control) and carrageenan-
treated (Inflammation) wild type mice (wt) and L1 mice are shown. Inflammation produced significantly increased responses in wild type (n = 6,
overall ANOVA P < 0.01), but not in L1 (n = 5) spinal cords.
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quency stimulation of C-fibers. Interestingly, BDNF
-/+
mice were able to develop a small amplitude enhance-
ment of reflexes, suggesting that the quantitative expres-
sion of BDNF in the spinal cord is correlated with the
ability to develop long-term forms of spinal plasticity.
DREAM transgenic mice express normal levels of TrkB
receptors in the spinal cord and therefore we were able
to test the effects of exogenous applications of BDNF to
the isolated spinal cord. BDNF produced a similar
enhancement of spinal responses to afferent inputs in
spinal cords from wild type and L1 mice, suggesting that
t h es p i n a lc o r df r o mL 1m i c ed o e sn o tr e c e i v ee n o u g h
BDNF from primary afferents after low frequency
stimulation of C-fibers or after inflammation. The
absence of induction in BDNF expression in dorsal root
ganglia from L1 mice following inflammation supports
this idea.
Conclusions
Transgenic L1 mice show a state of basal hyperalgesia
most likely sustained by low spinal cord levels of dynor-
phin and which is not related to anomalies in Kv
expression or function. More importantly, our work sug-
gests that the reduced hyperalgesic response in L1 mice
following peripheral inflammation and the reduced cen-
tral sensitization is mostly due to deficient BDNF input
in the spinal cord from primary afferents.
Figure 7 L1 mice lack spinal cord potentiation. (A) Number of spikes elicited by A-fiber intensity stimuli before and after administration of a
C-fiber specific conditioning stimulus consisting of 240 shocks (200 μA, 200 μs at 2 Hz). Wild type (wt) (n = 5) mice developed a large and
significant increase (One-way ANOVA, Bonferroni post-test, P < 0.01), whereas L1 (n = 6) mice did not show any change in the number of
elicited spikes. (B) Representative original recordings obtained from wild type (wt) and L1 mice before and 2 h after C-fiber conditioning. Bottom
panel, shows a representative original recording of the absence of potentiation in wild type mice 2 h after A-fiber conditioning. (C and D)
Number of spikes in ventral roots by graded dorsal root stimulation immediately before (Preconditioning) and 2 h after conditioning
(Postconditioning), obtained from wild type (wt) (n = 5) and L1 (n = 6) mice.
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Page 10 of 14Figure 8 The levels of BDNF in L1 mice are not sufficient for spinal sensitization. (A) Time course for ventral root responses to a series of
A-fiber intensity stimuli, before and after C-fiber specific conditioning (200 μA, 200 μs at 2 Hz). Data were obtained from spinal cords of wild
type (wt) (n = 6), BDNF
+/- (n = 3) and BDNF
-/- (n = 5) mice. In the BDNF
+/- group, DR-VRRs were larger in the 2 h postconditioning compared to
the preconditioning period (One-way ANOVA, Bonferroni post-test, P < 0.05). In the BDNF
-/- group the conditioning stimulus failed to modify DR-
VRRs. (B and C) Ventral root responses by graded stimuli applied to the dorsal root before and after prolonged superfusion of exogenous BDNF,
obtained from wild type (wt) (n = 5) and L1 (n = 6) mice. (D) BDNF mRNA levels in DRG were measured by quantitative PCR before, 3 and 5
days after intraplantar injection of complete Freund’s adjuvant in wild type (wt) (n = 6) and L1 (n = 6) adult mice. The mRNA levels are
expressed as ratio to HPRT mRNA levels. * Refers to comparison with wild type and # refers to comparison with day 0. Statistically significant
differences between groups were measured by One-way ANOVA with Bonferroni post-test. *** and ###, P < 0.001. (E) BDNF protein levels in
lumbar spinal cord 36 h after intraplantar injection of saline or complete Freund’s adjuvant in wild type (wt) (n = 3+3) and L1 (n = 3+3) adult
mice. Pools of the three mice in each experimental group were analyzed. The immunoreactive bands and densitometry quantification are
shown. BDNF values were corrected by b-actin levels.
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Animals and behavioral analysis
Experiments were performed with C57B/6×CBA mice.
BDNF
-/- mice were kindly provided by Dr. J. Alberch
(University of Barcelona). The generation of DREAM
transgenic mice has been described [7]. Experiments
were performed in adult male mice, homozygous for the
transgene (line L1) and in wild type mice. Mice were
housed five per cage in a temperature (21 ± 1°C) and
humidity (65 ± 10%) controlled room with a 12-/12- h
light/dark cycle (lights on from 8 am to 8 pm hours)
with food and water ad libitum. Experiments took place
during the light phase. Behavioral tests and animal care
were conducted in accordance with the standard ethical
guidelines (European Communities Directive 86/609
EEC; National Institutes of Health 1995) and approved
by the local ethical committee (CNB-UAH). All experi-
ments were carried out in blind conditions. Behavioral
testing by plantar test, tail flick, writhing test and von
Frey hairs were performed as described [24,40-42].
Inflammation was induced by unilateral intraplantar
injection of carrageenan (30 mg/ml in saline; 20 μl
injection volume) or complete Freund adjuvant (50 μl)
in P6-10 or adult mice.
RNA extraction and quantitative PCR
RNA from wild type and L1 spinal cord and dorsal root
ganglia was prepared using TRIzol (Invitrogen) and the
RNAeasy Mini Kit (Qiagen). RNA was quantified and
the quality was assessed with a 2100 Bioanalyzer (Agilent).
Quantitative real-time PCR for endogenous DREAM and
mutant daDREAM was performed using a pair of primers
able to amplify both: forward 5’-CACCTATGCA-
CACTTCCTCTTC A-3’ and reverse 5’-ACCACAAAGT-
CCTCAAAGTGGAT-3’ and two TaqMan MGB probes;
FAM-5’-TGCCTTCGATGCTGAT-3’-MGB and VIC-5’-
CGCCTTTGCTGCGGC-3’-MGB, specific for DREAM
and daDREAM, respectively. The results were normalized
by quantification of HPRT mRNA using the specific pri-
mers; forward 5’-TTGGATACAGGCC AGACTTTGTT-
3’ and reverse 5’-CTGAAGTACTCATTATAGTCAAGG-
GCATA-3’, and the probe FAM-5’-TTGAAATTCCAGA-
CAAGTTT-3’-MGB. Quantitative PCR for prodynorphin,
BDNF and TrkB were performed using kits from Applied
Biosystems.
Western blot analysis
Lumbar segments (L4 and L5) were dissected, frozen at
-70°C and homogenized in extraction buffer [100 mM
PIPES, pH 7.0; 0.5 M NaCl; 0.2% Triton-X 100; 2% BSA;
2 mM EDTA; protease inhibitors Complete Mini
(Roche)]. After centrifugation at 16,000× g for 30 min,
spinal cord extracts were resolved in SDS-PAGE and
transferred to PVDF membranes (Millipore). Antibodies
against b-actin (clone AC-15, Sigma) and BDNF (affinity
purified sheep anti-BDNF, OSB00026A, Osense) were
used and blots were developed using ECL (Supersignal
West Dure, Pierce). Band intensity were quantified using
the software QuantityOne (Biorad) and related to b-
actin to correct for protein loading.
In vitro spinal cord preparation and dorsal root
stimulation
Wild type and transgenic (L1) 6-11 days-old mice of
either sex weighing between 4.3 and 9.7 g were anaes-
thetized with urethane (2 g/Kg i.p.) and spinal cords
were extracted following a rostrocaudal laminectomy
[43]. Entire or hemisected spinal cords (for ventral root
or single cell recordings) were pinned down to a
Sylgard-based recording chamber and maintained with
oxygenated artificial cerebrospinal fluid (ACSF) at room
temperature (22 ± 1°C). The composition of the ACSF
was: (in mM) NaCl 127, KCl 1.9, KH2PO4 1.5, MgSO4
1.3, CaCl2 2, NaHCO3 22, glucose 10, (pH 7.4). One
lumbar dorsal root (L4-L5) was placed in a tight fitting
glass suction electrode and electrically stimulated to
activate afferent fibers. Single stimuli of 200 ms duration
were applied at a range of intensities to activate A-fibers
or all fibers in the dorsal root [26]. Wind-up stimuli
consisted of 20 C-fiber intensity shocks (200 μs, 200
μA) applied at 1 Hz. Conditioning stimuli to produce a
long-lasting enhancement of dorsal root-ventral root
reflexes (DR-VRRs) consisted of 240 C-fiber intensity
shocks (200 μs, 200 μA) delivered at 2 Hz.
Ventral root recordings
L4-L5 ventral roots were placed in a suction electrode
to record averaged activity from motoneurons. Record-
ings were made with a Cyberamp (Axon Instruments,
CA, USA) in AC mode as previously described [26]. AC
recordings showed individual fast events, or spikes or
groups of spikes, reflecting the simultaneous firing of
action potentials in a group of motoneurons. The num-
ber of such events was quantified using amplitude cri-
teria as previously described [44]. Responses to single
stimuli were quantified as the number of spikes counted
in a time window between 20 ms and 4 s from the sti-
mulus artifact. Responses to trains of stimuli were quan-
tified as the number of spikes within 20 ms and 0.95 s
after each stimulus artifact of the train.
Current and voltage clamp recordings
Electrodes were pulled from borosilicate glass tubing
with internal filament using a horizontal puller (Sutter
instruments, Novato, CA, USA) giving resistances within
the range of 6-9 MΩ. Internal solution consisted of: (in
mM) KCl 30, EGTA 3, HEPES 40, MgCl2 2, potassium
acetate 95, CaCl2 0.5, Na2-ATP 3, Na-GTP 0.3 (pH 7.4).
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fier (Axon Instruments, CA, USA) and analyzed offline
with Spike 2 and Signal software (CED, Cambridge Elec-
tronic Designs, Cambridge, UK). Electrode tracking as
well as current and voltage recordings were performed
using protocols and procedures explained in full else-
where [45]. Transient potassium currents sensitive to
4-aminopyridine and insensitive to tetraethyl ammo-
nium were isolated in the presence of 0.5 μMt e t r o d o -
toxin to block sodium currents and 100 μM cadmium
chloride to block calcium and calcium-activated potas-
sium currents as previously described [46,47].
Drugs and chemicals
Carrageenan lambda, Complete Freund Adjuvant (CFA),
cadmium chloride (CdCl2), tetraethyl ammonium (TEA),
4-aminopyridine (4-AP) and the components for the
ACSF and the intracellular solution were from Sigma-
Aldrich (Spain). Tetrodotoxin (TTX) was from Tocris
Bioscience (Bristol, UK) and BDNF from Peprotech
(CA, USA).
Data analysis
Statistical analysis and curve fittings were performed
using Prism 4.0 (GraphPad Software, USA). Differences
between pairs of mean values were analyzed using the
Mann-Whitney test or One-way ANOVA. Responses to
dorsal root stimulation and intracellular pulses were
quantified in terms of number of spikes against intensity
of dorsal root stimulus or intracellular pulse respec-
tively, and the resulting curves were analyzed using
Two-way ANOVA. Data of normalized conductance,
activation and inactivation curves were treated as
previously reported [45]. Curves were compared by
Two-way ANOVA followed by Bonferroni post-tests.
Data is expressed as mean ± SEM, unless otherwise
stated.
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